Two-year treatment outcomes after anti-vascular endothelial growth factor therapy in age-related macular degeneration with type 2 macular neovascularization in Japanese patients
Japanese Journal of Ophthalmology · 2025
DOI: 10.1007/s10384-025-01178-3 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Japanese Journal of Ophthalmology, 2025. Verfasst von Yosuke Fukuda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Bevacizumab, Macula Lutea, Ranibizumab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research.
Abstract (Originalsprache)
PURPOSE: Neovascular age-related macular degeneration (nAMD) with type 2 macular neovascularization (MNV) has a relatively good responsiveness to anti-vascular endothelial growth factor (anti-VEGF) therapy compared to type 1 MNV. This study aimed to analyze the treatment outcomes of nAMD patients with type 2 MNV and identify factors associated with fluid recurrence. STUDY DESIGN: Retrospective observational study. METHODS: This study included treatment-naïve nAMD patients with type 2 MNV but without type 1 MNV, who received 3-monthly anti-VEGF injections as the loading phase and were followed up for over 2 years. The treatment outcomes were compared between proactive (PA) and reactive regimen (RA) groups. In addition, we investigated the factors associated with fluid recurrence in the RA group. RESULTS: This retrospective study included 65 eyes from 65 patients. Best-corrected visual acuity (BCVA) and central macular thickness significantly improved in both the PA and RA groups. Although there was no significant difference between the two groups, the RA group showed a trend towards better BCVA. The presence of fluid three or four months after the initial injection was associated with fluid recurrence in the RA group (p = 0.02). CONCLUSION: For nAMD patients with type 2 MNV, a proactive regimen is generally preferred. However, for nAMD patients with type 2 MNV achieving fluid resolution after the loading phase, it may be possible to maintain BCVA and reduce the number of anti-VEGF injections by following a reactive regimen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
- Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. asshyharyu@gmail.com.
Förderung
- Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research
Zitieren
APA
Fukuda, Y., Shiose, S., Notomi, S., Maehara, Y., Mori, K., Hashimoto, S., Kano, K., Ishikawa, K., & Sonoda, K. H. (2025). Two-year treatment outcomes after anti-vascular endothelial growth factor therapy in age-related macular degeneration with type 2 macular neovascularization in Japanese patients. Japanese Journal of Ophthalmology. https://doi.org/10.1007/s10384-025-01178-3
Vancouver
Fukuda Y, Shiose S, Notomi S, Maehara Y, Mori K, Hashimoto S, et al. Two-year treatment outcomes after anti-vascular endothelial growth factor therapy in age-related macular degeneration with type 2 macular neovascularization in Japanese patients. Japanese Journal of Ophthalmology. 2025. doi:10.1007/s10384-025-01178-3
BibTeX
@article{Fukuda2025,
author = {Fukuda, Yosuke and Shiose, Satomi and Notomi, Shoji and Maehara, Yusuke and Mori, Kenichiro and Hashimoto, Sawako and Kano, Kumiko and Ishikawa, Keijiro and Sonoda, Koh-Hei},
title = {Two-year treatment outcomes after anti-vascular endothelial growth factor therapy in age-related macular degeneration with type 2 macular neovascularization in Japanese patients},
journal = {Japanese Journal of Ophthalmology},
year = {2025},
doi = {10.1007/s10384-025-01178-3}
}
EUVIMED